Area of research
Immunology · Oncology
Research interest
Research interests include Immune Cell Function and Interaction, CAR-T cell therapy research, Immunotherapy and Immune Responses, and Cancer Immunotherapy and Biomarkers.
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy.
Protein-Capturing Microgel-Integrated Microneedle Array Patches for Enhanced Tip-Loading, Storage Stability, and Transdermal Delivery of Recombinant Proteins.
Spatial cartography of human thymus enables the geopositioning of lineage transcription factors in rare mimetic thymic epithelial cells.
Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells.
Supplementary Figure S2 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S3 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S1 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S11 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S10 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S2 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S13 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S8 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S4 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S3 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S7 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S17 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S5 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S9 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S1 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S16 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S15 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Table S4 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S12 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S14 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Data from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
Supplementary Figure S6 from Cortactin Suppresses mTOR-Dependent Senescence in Circulating Tumor Cells
FLI1 Expression in Invasive Breast Carcinoma: Clinicopathological Correlations and Prognostic Implications.
Supplementary Data from IL12/18/21 Preactivation Enhances the Antitumor Efficacy of Expanded γδT Cells and Overcomes Resistance to Anti–PD-L1 Treatment
Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases
A high-density microfluidic bioreactor for the automated manufacturing of CAR T cells